Little Help from Lucentis for Vitreous Hemorrhage (CME/CE)

(MedPage Today) -- Patients with vitreous hemorrhage related to diabetic retinopathy derived minimal short-term benefit from treatment with the angiogenesis inhibitor ranibizumab (Lucentis), results of a randomized trial showed.
Source: MedPage Today Ophthalmology - Category: Opthalmology Source Type: news